IM Cannabis has short-squeeze potential: its float is a micro 603,200 shares, 12% of it is sold short and no shares are left to borrow, with fresh news and volume adding pressure. Remaining warrants, including those at $19 and $99, could lift the share count to about 780,000. x.com 

WhiteFiber is a live short-squeeze candidate, with 57.1% of its float sold short and 3.0 days to cover, and the move has not happened yet. Short interest data settles about a month behind, with new figures due September 1. x.com 

Fluence faces price pressure because its freely tradable float is expanding sharply while total shares stay the same. Even if the roughly 97 million shares are not sold right away, buyers won't chase knowing heavy selling could come at any time. The scarcity premium of a small float disappears as it widens, and more tradable shares also mean more stock to borrow for shorting. Fluence is a good company; the objection is to how this was handled. x.com 

China SXT Pharmaceuticals is a short-squeeze candidate: short interest exceeds 20%, institutional ownership exceeds 100%, no shares are left to borrow and the cost to borrow is over 500%. It has the same setup as other low-float, high-short-interest plays; after coiling all day, a pop on incoming volume is only a matter of time because shorts are trapped. x.com  x.com